Hypoxystat is an orally active hypoxia mimetic. HypoxyStat increases Hemoglobin ’s oxygen affinity, limiting oxygen offloading to the tissues and inducing local tissue hypoxia. Hypoxystat reduces Iba1 + cells. HypoxyStat causes systemic hypoxia. Hypoxystat effectively rescues hyperglycemia in mouse models of type 1 and type 2 diabetes. HypoxyStat not only extends lifespan but also rescues key neuropathological and behavioral deficits in the premier mouse model of Leigh syndrome [1] [2].
In Vivo, HypoxyStat (600 mg/kg; p.o.; daily; 2.5 weeks) potently rescues high-fat diet-induced hyperglycemia and normalizes glucose tolerance in male C57BL/6J mice[1]. HypoxyStat (200-600 mg/kg; oral gavage; daily/every other day/single dose) extends lifespan by 3-4× and rescues neuropathological, behavioral, and physiological deficits in Ndufs4 knockout mice when administered preventatively, and retains efficacy when initiated at a late disease stage[2].
In Vitro, HypoxyStat (10 mM; 1 h) increases oxygen-hemoglobin binding affinity in human red blood cells, as indicated by an ~82% decrease in p50[2].
References:
[1]. Martí-Mateos Y, et al. Red blood cells serve as a primary glucose sink to improve glucose tolerance at altitude. Cell Metab. 2026 Feb 19:S1550-4131(26)00018-5.
[2]. Blume SY, et al. HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity. Cell. 2025;188(6):1580-1588.e11.
In Vivo, HypoxyStat (600 mg/kg; p.o.; daily; 2.5 weeks) potently rescues high-fat diet-induced hyperglycemia and normalizes glucose tolerance in male C57BL/6J mice[1]. HypoxyStat (200-600 mg/kg; oral gavage; daily/every other day/single dose) extends lifespan by 3-4× and rescues neuropathological, behavioral, and physiological deficits in Ndufs4 knockout mice when administered preventatively, and retains efficacy when initiated at a late disease stage[2].
In Vitro, HypoxyStat (10 mM; 1 h) increases oxygen-hemoglobin binding affinity in human red blood cells, as indicated by an ~82% decrease in p50[2].
References:
[1]. Martí-Mateos Y, et al. Red blood cells serve as a primary glucose sink to improve glucose tolerance at altitude. Cell Metab. 2026 Feb 19:S1550-4131(26)00018-5.
[2]. Blume SY, et al. HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity. Cell. 2025;188(6):1580-1588.e11.